Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
What changed this week, this month — regulation, research, industry. Reported with primary sources, not press-release copy. New entries appear here as they ship.
FDA's own scientists proposed no on all seven peptides. Its advisory committee voted yes on six — BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax — and rejected only Emideltide. The full vote record, from FDA's own broadcast, and what it changes.
Our pre-meeting preview of the July 23–24 PCAC review of seven peptides for the 503A bulks list, setting out FDA's position going in: for every one of them, the agency's proposed answer was the same. Do not add it. The committee has since voted the other way on six of the seven.
The agency posted a batch of warning letters on June 16 — 25 of them aimed at compounded semaglutide and tirzepatide marketing. We pulled five of the letters and grouped what FDA actually objected to, who got named, and how it lines up with the parallel rulemaking that closed June 29.